NASH: Madrigal Files Resmetirom In EU While US Action Date Closes In

Resmetirom, which could become the first approved treatment for non-alcoholic steatohepatitis, is among 11 new drugs that the European Medicines Agency has started to review for potential EU approval. Meanwhile, a decision on whether to approve the drug in the US is due on 14 March.

Liver health
NASH is a more advanced form of non-alcoholic fatty liver disease • Source: Shutterstock

The European Medicines Agency has begun reviewing a new batch of drugs for potential pan-EU marketing approval, including resmetirom, Madrigal Pharmaceuticals’ THR-β agonist, which is awaiting a decision tomorrow on whether it will become the first approved treatment for non-alcoholic steatohepatitis (NASH) in the US.

Resmetirom is a once-daily, oral drug designed to target the key underlying causes of NASH, a potentially lucrative market that...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Europe

  • EU Biosimilar Filings, Opinions And Approvals

     
    • By 

    <p>Executive Summary</p> <p>A list of EU biosimilar filings, CHMP opinions and EU marketing authorizations, including details of the biosimilar company, the brand name/INN, indication(s), the reference product/company, and the date and type of event.</p>

  • EU Pharma Reform: What You Need to Know Now

     

    As the reform of the EU pharmaceutical legislation progresses through the legislative process, the Pinks Sheet offers an infographic highlighting some of the key changes being proposed that will reshape the way drug companies run their business.

  • New EU Approvals

    <p>Executive Summary<p> <p>The Pink Sheet's list of EU centralized approvals of new active substances has been updated to add six new products, incl/ding Ixchiq, Valneva's chikungunya virus vaccine</p>

More from Geography